In this podcast, Irena Milobratović, CEO of Indaea Co. (@indaea_co), speaks with Igor Balaž, CEO of Neovivum Technologies about New Approach Methodologies (NAMs) and their growing role in biomedical research.
They discuss the limitations of traditional animal models, particularly in oncology, and how human-derived models, organ-on-chip systems, advanced data analysis, and digital twins can provide more human-relevant approaches to studying disease and treatment response. The podcast also explores the value of combining experimental NAMs with their digital counterparts, the challenges of working with heterogeneous biological and clinical data, and the importance of model uncertainty, transparency, standardization, and robust evidence.
Finally, they consider what will be needed for NAMs and digital twins to gain greater regulatory acceptance and become more firmly integrated into preclinical research and drug development.